Although this BC subtype has the most favorable prognosis in the general BC population7, CHEK2 c.1100delC carriers have a higher risk of developing contralateral breast cancer (CBC) and worse survival3, 4, 6, 8, 9 compared to non-carriers. This evidence concerns the gene CHEK2 and complete blood cell count.